Intellia Says Sickle Cell Therapy Still ‘Wide Open’ As Novartis And Others Exit
Graphite Bio And Sangamo Also Dropping Out
A long-anticipated pruning back of the ev vivo gene therapy pipeline for sickle cell disease has arrived with Novartis, Graphite Bio and Sangamo each dropping projects, but some challengers are looking ahead to a future of in vivo approaches to the condition.
